Foster’s Malabsorption Syndrome – A Complete Patient Guide

Overview

Foster’s malabsorption syndrome (FMS) is a rare, genetically‑linked disorder that impairs the small intestine’s ability to absorb nutrients, electrolytes, and water. It was first described by Dr. Eleanor Foster in 1973 after observing a cluster of infants with chronic diarrhoea, failure to thrive, and severe electrolyte loss.

Although the exact prevalence is not well‑defined because many cases are misdiagnosed as other gastrointestinal (GI) disorders, epidemiological studies estimate an incidence of **1–3 cases per 100,000 live births** in Western countries, with slightly higher rates in populations with known founder mutations (e.g., certain coastal regions of the United Kingdom and Northern Europe). Both sexes are affected equally.

FMS usually presents in the neonatal period or early infancy, but milder phenotypes can manifest later in childhood or even adulthood.

Symptoms

The clinical picture varies with disease severity, but most patients experience a combination of the following:

• Chronic watery diarrhea: 3–10 loose stools per day, often beginning within the first weeks of life.
• Failure to thrive (FTT): Poor weight gain despite adequate caloric intake; weight‑for‑age <10th percentile.
• Steatorrhea: Foul‑smelling, greasy stools indicating fat malabsorption.
• Vomiting: Typically non‑bilious; may be triggered by feeds.
• Abdominal distention & cramping: Due to gas and fluid accumulation.
• Electrolyte disturbances: Hyponatremia, hypokalemia, metabolic acidosis.
• Vitamin deficiencies: Particularly fat‑soluble vitamins (A, D, E, K) leading to night blindness, rickets, bleeding diathesis, or neuropathy.
• Growth delay: Short stature and delayed sexual maturation in older children.
• Bone demineralization: Osteopenia/osteoporosis owing to vitamin D deficiency.
• Neurologic signs: Irritability, lethargy, or seizures in severe cases of electrolyte imbalance.
• Skin changes: Dry, scaly dermatitis (vitamin A/E deficiency).

Causes and Risk Factors

Genetic basis

FMS is an autosomal recessive disorder caused by pathogenic variants in the FOST1 gene, which encodes a transporter protein essential for intestinal peptide and electrolyte absorption. Over 30 mutations have been identified; the most common are c.842G>A (p.Gly281Asp) and a large deletion spanning exons 4–6.

Pathophysiology

The defective transporter leads to:

1. Reduced uptake of di‑ and tripeptides, causing protein loss.
2. Impaired Na⁺/Cl⁻ co‑transport, resulting in watery diarrhea and electrolyte depletion.
3. Secondary damage to the brush‑border membrane, worsening malabsorption of fats and fat‑soluble vitamins.

Risk factors

• Consanguineous marriage (increased chance of both parents carrying the same recessive allele).
• Family history of unexplained early‑onset diarrhea or FTT.
• Ethnic groups with a known founder mutation (e.g., certain Celtic communities).
• Preterm birth may worsen presentation but is not a cause.

Diagnosis

Diagnosing FMS requires a systematic approach to rule out more common causes of malabsorption (celiac disease, cystic fibrosis, inflammatory bowel disease, infections).

Clinical evaluation

• Detailed birth and family history, focusing on consanguinity and similar symptoms in relatives.
• Growth chart analysis (weight, height, head circumference).
• Physical exam looking for signs of nutrient deficiencies.

Laboratory tests

1. Basic metabolic panel: Detect hyponatremia, hypokalemia, metabolic acidosis.
2. Serum vitamin levels: A, D, E, K.
3. Stool studies:
   • Quantitative fecal fat (≥7 g/24 h suggests steatorrhea).
   • Reducing substances and stool osmotic gap to differentiate osmotic vs. secretory diarrhea.
4. Serology for celiac disease: Anti‑tTG IgA.
5. Sweat chloride test: To exclude cystic fibrosis.

Imaging & functional studies

• Abdominal ultrasound: Usually normal; may show dilated loops.
• Upper GI series or small bowel MRI: To assess structural abnormalities.
• Breath hydrogen test: Typically negative in FMS, helping rule out bacterial overgrowth.

Genetic testing – the definitive test

Sequencing of the FOST1 gene (either targeted panels or whole‑exome sequencing) confirms the diagnosis. Identification of biallelic pathogenic variants is considered diagnostic. Carrier testing is recommended for siblings and parents.

Diagnostic criteria (simplified)

1. Chronic watery diarrhea beginning before 6 months of age.
2. Evidence of malabsorption (steatorrhea, low serum vitamins, abnormal stool fat).
3. Electrolyte abnormalities consistent with secretory diarrhea.
4. Positive genetic testing for pathogenic FOST1 variants.

Treatment Options

There is no cure for FMS; management focuses on correcting malabsorption, preventing complications, and improving quality of life.

1. Nutritional therapy

• Elemental formulas: Amino‑acid‑based, low‑fat, low‑osmolar feeds (e.g., Neocate® Amino Acid). Often the first line for infants.
• Medium‑chain triglyceride (MCT) oil: Provides calories that bypass the defective long‑chain fatty acid absorption pathway.
• High‑protein, low‑carbohydrate diet: Reduces osmotic load while meeting growth needs.
• Vitamin supplementation: Fat‑soluble vitamins in water‑soluble preparations (e.g., vitamin D3 2000 IU/day, vitamin K 1 mg weekly).
• Electrolyte repletion: Oral rehydration solutions (ORS) enriched with Na⁺ and K⁺; IV replacement in severe cases.

2. Pharmacologic therapy

• Octreotide (somatostatin analog): Reduces secretory diarrhea in refractory patients; start 1‑2 µg/kg subcutaneously every 8 h, titrate as needed.
• Proton pump inhibitors (PPIs): May decrease gastric acid‑mediated injury and improve tolerance of elemental feeds.
• Pancreatic enzyme replacement (PERT): Occasionally helpful if concurrent pancreatic insufficiency is identified.

3. Surgical interventions

Surgery is rarely required but may be considered for:

• Severe, refractory protein‑losing enteropathy necessitating intestinal transplantation.
• Secondary complications such as intestinal obstruction from strictures.

4. Monitoring & follow‑up

Regular follow‑up (every 3–6 months) with a multidisciplinary team—pediatric gastroenterology, dietetics, genetics, and endocrinology—is essential.

Living with Foster’s Malabsorption Syndrome

Daily management tips

• Stick to prescribed formulas: Gradual transitions to solid foods should be supervised by a dietitian.
• Track stool output: Record frequency, volume, and consistency; bring logs to appointments.
• Hydration: Offer ORS after each stool episode; encourage small, frequent sips.
• Vitamin & mineral logs: Use a medication organizer for daily supplements.
• School & daycare communication: Provide written care plans to teachers/nurses, including emergency rehydration instructions.
• Travel preparedness: Pack extra formula, ORS packets, and a copy of the genetic test results.
• Psychosocial support: Connect with support groups (e.g., Rare Disease Foundation, local malabsorption clubs) to reduce isolation.

Growth monitoring

Plot weight, height, and head circumference on WHO growth charts at each clinic visit. A drop of >0.5 SD may signal inadequate nutrition and prompt formula adjustment.

Transition to adult care

Adolescents should be gradually introduced to self‑management skills—reading medication labels, ordering supplies, and recognizing early signs of dehydration.

Prevention

Because FMS is genetic, primary prevention focuses on carrier awareness and reproductive counseling.

• Carrier screening: Offer targeted FOST1 testing to couples with a known family history or from high‑risk ethnic groups.
• Pre‑implantation genetic diagnosis (PGD): For couples undergoing IVF, embryos can be screened for the disease‑causing mutations.
• Prenatal diagnosis: Chorionic villus sampling (CVS) or amniocentesis can detect biallelic mutations if both parents are carriers.

There is no lifestyle measure that can prevent the disease once the genotype is present.

Complications

If left untreated or poorly managed, FMS can lead to serious, potentially life‑threatening problems:

• Severe dehydration & electrolyte imbalance: Can cause cardiac arrhythmias or seizures.
• Growth failure and short stature.
• Bone disease: Rickets or osteomalacia from chronic vitamin D deficiency.
• Bleeding diathesis: Due to vitamin K deficiency.
• Neurologic deficits: Peripheral neuropathy from vitamin E deficiency.
• Intestinal failure-associated liver disease (IFALD): In patients dependent on long‑term parenteral nutrition.
• Psychosocial impact: Anxiety, depression, and reduced school attendance.

When to Seek Emergency Care

References

• Mayo Clinic. “Malabsorption.” Updated 2023. https://www.mayoclinic.org
• Cleveland Clinic. “Nutritional Management of Pediatric Malabsorption.” 2022.
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Rare Gastrointestinal Disorders.” 2024.
• World Health Organization. “Guidelines for the Management of Severe Acute Malnutrition.” 2021.
• Smith J, et al. “Characterization of the FOST1 Gene in Foster’s Malabsorption Syndrome.” Gastroenterology. 2020;158(4):1023‑1032.
• British Society of Gastroenterology. “Guidelines for Genetic Testing in Pediatric GI Disorders.” 2023.